Change Condition
Patients HCPs
This site is for US residents only.

For adults with moderate to severe hidradenitis suppurativa

Purple to pink gradient background

REAL RESULTS. REAL RELIEF FROM HS SYMPTOMS.

COSENTYX® (secukinumab) helps adults with moderate to severe hidradenitis suppurativa (HS) find real relief at 16 weeks†:

50-down

50% REDUCTION

At least a 50% reduction in the number of inflammatory bumps and abscesses

down arrow

NO INCREASE

No increase in the number of abscesses and/or draining tunnels

In the 2 clinical trials, 41% and 43% of adults taking COSENTYX 300 mg every 4 weeks (after 5 initial weekly doses) achieved at least a 50% reduction in the number of inflammatory bumps and abscesses, with no increase in the number of abscesses and/or draining tunnels at 16 weeks vs 29% and 26% taking placebo.

†COSENTYX 300 mg every 4 weeks (after 5 initial weekly doses).

75 percent of people had zero flares

COSENTYX can help reduce HS flares

In 1 of 2 clinical trials, 75% of adults taking COSENTYX had zero flares at week 16.†
 

In the same clinical trial, 25% of adults taking COSENTYX† had 1 or more flares at week 16 vs 36% taking placebo. In the second trial, the same results were not seen.
 

A flare was defined as a greater than 25% increase in the number of inflammatory bumps and abscesses, with a minimum increase of 2 inflammatory bumps or abscesses.

†COSENTYX 300 mg every 4 weeks (after 5 initial weekly doses).

1 year later, playing basketball

At 1 year of treatment†

The 1-year information presented below is exploratory data‡ and it is unknown if symptom improvement was due to COSENTYX or not. Everyone experiences treatment differently. Results may vary.

†COSENTYX 300 mg every 4 weeks (after 5 initial weekly doses).
‡We cannot make conclusions from exploratory data, but it is useful to help guide future research.

Bumps and Abscesses

In the 2 clinical trials, at 1 year, 58% and 65% (56 out of 96, 61 out of 94 patients respectively) had at least a 50% reduction in the number of inflammatory bumps and abscesses, with no increase in the number of abscesses and/or draining tunnels.

Flares

At 1 year, 71.6% and 73.5% (78 out of 109 and 75 out of 102 patients, respectively) did not experience a flare. In clinical trials, flare was defined as a greater than 25% increase in the number of inflammatory bumps and abscesses, with a minimum increase of 2 inflammatory bumps or abscesses.

Talk to your dermatologist about your treatment goals, including bumps, flares, and skin pain.

Proven experience

Since 2015, over 4.3 million COSENTYX prescriptions have been filled§ in the United States.∥

COSENTYX has had a well-studied safety profile since its launch in 2015, when it was approved to treat adults with moderate to severe plaque psoriasis. In 2016, it was FDA approved to treat active ankylosing spondylitis and active psoriatic arthritis in adults. Then, it was approved in 2020 to treat adults with non-radiographic axial spondyloarthritis. It has since been approved to treat children with plaque psoriasis (6 years and older), psoriatic arthritis (2 years and older), and enthesitis-related arthritis (4 years and older). COSENTYX was FDA approved to treat adults with moderate to severe hidradenitis suppurativa (HS) in 2023.

The COSENTYX HS clinical trials were the largest clinical trial program for HS to date.

§Across all indications combined. 
∥As of December 2023.

 

*Limitations apply. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.